JPMorgan Aims to Construct London's Largest Office Building
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: WSJ
New Construction Project: JPMorgan Chase, led by Jamie Dimon, is set to build London's largest office block in Canary Wharf.
Completion Timeline: The project is expected to be completed in the 2030s.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JPM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JPM
Wall Street analysts forecast JPM stock price to rise
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 286.160
Low
260.00
Averages
341.38
High
400.00
Current: 286.160
Low
260.00
Averages
341.38
High
400.00
About JPM
JPMorgan Chase & Co. is a financial holding company. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. The Company operates through three segments: Consumer & Community Banking (CCB), Commercial & Investment Bank (CIB), and Asset & Wealth Management (AWM). Its CCB segment offers products and services to consumers and small businesses through bank branches, ATMs, digital and telephone banking. Its CIB segment consists of banking and payments and markets and securities services, and offers a suite of investment banking, lending, payments, market-making, financing, custody and securities products and services to a global base of corporate and institutional clients. AWM segment offers investment and wealth management solutions. It offers multi-asset investment management solutions, retirement products and services, brokerage, custody, estate planning, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
JPMorgan Chase to Host Q1 2026 Earnings Call
- Earnings Call Schedule: JPMorgan Chase will hold a conference call on April 14, 2026, at 8:30 a.m. (ET) to review its Q1 2026 financial results, with results expected to be released at 7:00 a.m. (ET), ensuring timely access to critical information for investors.
- Webcast and Materials: The live audio webcast and presentation slides will be available on JPMorgan's Investor Relations website, enhancing transparency and facilitating access to relevant data for investors, thereby increasing the firm's credibility in the market.
- Public Notification Channels: JPMorgan will notify the public of the financial results through social media outlets @JPMorgan and @Chase, as well as a press release, ensuring broad information dissemination and enhancing the company's brand visibility.
- Conference Call Access Information: The public can join the call by dialing 1 (888) 324 3618 in the U.S. and Canada or +1 (312) 470 7119 internationally, using passcode 1364784#, providing a convenient way for investors to engage and enhancing interaction between the company and its stakeholders.
See More
JPMorgan Halts $5.3B Debt Deal for Qualtrics Amid AI Concerns
- Debt Deal Halted: A JPMorgan-led banking group has suspended a $5.3 billion debt deal for software firm Qualtrics International due to concerns over AI disruption, indicating a lack of confidence in the market regarding the company's future.
- Acquisition Plans in Jeopardy: Qualtrics was set to acquire data analytics firm Press Ganey Forsta for $6.75 billion, but the financing difficulties have cast uncertainty on this transaction, potentially impacting its market expansion strategy.
- Market Reaction to Financing: Banks were initially planning to sell $3.3 billion in leveraged loans and $2 billion in high-yield bonds in March, but investor concerns about Qualtrics' exposure to the software downturn have derailed these financing plans.
- Existing Loan Depreciation: Qualtrics' existing approximately $1.5 billion loan has fallen to about 86 cents on the dollar in secondary trading from close to par value of 100 cents in February, reflecting market worries about its financial health.
See More
Japan's Exports Rise 4.2% in February but Slow Down
- Export Growth Slowdown: Japan's exports rose 4.2% year-on-year in February, exceeding the 1.6% expected by economists but significantly down from January's 16.8%, indicating signs of weakening global demand that could impact future economic recovery.
- Major Market Declines: Exports to China fell by 10.9% and shipments to the U.S. dropped by 8%, particularly with a 14.8% decline in auto exports, which may reduce Japan's competitiveness in the global automotive market and affect related supply chains.
- Strong Regional Market Performance: Despite declines in major trading partners, exports to Hong Kong surged by 32.3% and to the ASEAN bloc increased by 5.1%, showcasing Japan's potential in diversifying markets, which could support future economic growth.
- Robust Semiconductor Exports: The value of semiconductor exports jumped by 25.1% year-on-year, becoming a key driver of overall export growth, indicating Japan's strong competitiveness in high-tech sectors that may attract further investment and collaboration opportunities.
See More
Edgewise Therapeutics Stock Rises on Analyst Price Target Boost
- Analyst Price Target Increase: Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, resulting in a stock price increase of over 2%, significantly outperforming the S&P 500's 0.3% rise, indicating strong market confidence in the company.
- Drug Development Potential: The analyst highlighted that Edgewise has several investigational programs that could position it favorably in the biotech sector, particularly the renewed interest in EDG-7500, a drug targeting hypertrophic cardiomyopathy, which may drive future growth.
- Impact of Clinical Data Release: Last week, Edgewise published long-term data on sevasemten for muscular dystrophy, showing that Becker muscular dystrophy patients stabilized function with treatment, contrasting sharply with expected functional decline, thereby laying a solid foundation for the company's future market performance.
- Multiple Drug Development Advantage: Edgewise is not only developing one high-potential drug but also two additional drugs in the high-demand cardiovascular segment, making its diversified development strategy a standout feature in the biotech industry and attracting investor interest.
See More
Analyst Raises Edgewise Price Target to $45
- Price Target Increase: Analyst Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, an increase of $11, reflecting confidence in the company's pipeline drug potential, which is expected to attract more investor interest.
- Positive Market Reaction: Following the price target increase, Edgewise's stock rose over 2% on Tuesday, significantly outperforming the S&P 500's 0.3% gain, indicating a bullish sentiment among investors towards the biotech firm.
- Pipeline Drug Potential: The analyst highlighted Edgewise's EDG-7500 drug targeting the high-demand market for hypertrophic cardiomyopathy (HCM), which could propel the company to a leading position in the biotech sector.
- Clinical Data Support: Recent long-term data from Edgewise's muscular dystrophy treatment sevasemten showed stabilization of function in Becker-type patients, contrasting sharply with expected declines from natural history data, further bolstering market confidence in its products.
See More
JPMorgan Chase's Stock Performance Disappoints
- Disappointing Revenue Growth: JPMorgan Chase's annualized revenue growth of 8.6% over the past five years is below the banking sector's standard, indicating a lack of competitive strength in revenue generation that may undermine investor confidence and limit future stock price appreciation.
- Weak Net Interest Margin: The bank's average net interest margin of 2.6% over the past two years reveals poor loan profitability, necessitating increased loan originations to compensate for lower earnings, which could elevate risk levels.
- Deteriorating Efficiency Ratio: Wall Street anticipates JPMorgan Chase's efficiency ratio will rise to 54% over the next 12 months, up from 51.7% last year, suggesting a decline in cost control capabilities that may further compress profit margins and impact overall financial health.
- Lack of Market Confidence: Despite the stock trading at $285.86 with a forward P/B ratio of 2.1, market sentiment remains skeptical about JPMorgan Chase's future performance, prompting analysts to recommend investors consider other stocks with greater potential, reflecting doubts about its long-term investment value.
See More
JPMorgan Chase to Host Q1 2026 Earnings Call
- Earnings Call Schedule: JPMorgan Chase will hold a conference call on April 14, 2026, at 8:30 a.m. (ET) to review its Q1 2026 financial results, with results expected to be released at 7:00 a.m. (ET), ensuring timely access to critical information for investors.
- Webcast and Materials: The live audio webcast and presentation slides will be available on JPMorgan's Investor Relations website, enhancing transparency and facilitating access to relevant data for investors, thereby increasing the firm's credibility in the market.
- Public Notification Channels: JPMorgan will notify the public of the financial results through social media outlets @JPMorgan and @Chase, as well as a press release, ensuring broad information dissemination and enhancing the company's brand visibility.
- Conference Call Access Information: The public can join the call by dialing 1 (888) 324 3618 in the U.S. and Canada or +1 (312) 470 7119 internationally, using passcode 1364784#, providing a convenient way for investors to engage and enhancing interaction between the company and its stakeholders.
See More
JPMorgan Halts $5.3B Debt Deal for Qualtrics Amid AI Concerns
- Debt Deal Halted: A JPMorgan-led banking group has suspended a $5.3 billion debt deal for software firm Qualtrics International due to concerns over AI disruption, indicating a lack of confidence in the market regarding the company's future.
- Acquisition Plans in Jeopardy: Qualtrics was set to acquire data analytics firm Press Ganey Forsta for $6.75 billion, but the financing difficulties have cast uncertainty on this transaction, potentially impacting its market expansion strategy.
- Market Reaction to Financing: Banks were initially planning to sell $3.3 billion in leveraged loans and $2 billion in high-yield bonds in March, but investor concerns about Qualtrics' exposure to the software downturn have derailed these financing plans.
- Existing Loan Depreciation: Qualtrics' existing approximately $1.5 billion loan has fallen to about 86 cents on the dollar in secondary trading from close to par value of 100 cents in February, reflecting market worries about its financial health.
See More
Japan's Exports Rise 4.2% in February but Slow Down
- Export Growth Slowdown: Japan's exports rose 4.2% year-on-year in February, exceeding the 1.6% expected by economists but significantly down from January's 16.8%, indicating signs of weakening global demand that could impact future economic recovery.
- Major Market Declines: Exports to China fell by 10.9% and shipments to the U.S. dropped by 8%, particularly with a 14.8% decline in auto exports, which may reduce Japan's competitiveness in the global automotive market and affect related supply chains.
- Strong Regional Market Performance: Despite declines in major trading partners, exports to Hong Kong surged by 32.3% and to the ASEAN bloc increased by 5.1%, showcasing Japan's potential in diversifying markets, which could support future economic growth.
- Robust Semiconductor Exports: The value of semiconductor exports jumped by 25.1% year-on-year, becoming a key driver of overall export growth, indicating Japan's strong competitiveness in high-tech sectors that may attract further investment and collaboration opportunities.
See More
Edgewise Therapeutics Stock Rises on Analyst Price Target Boost
- Analyst Price Target Increase: Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, resulting in a stock price increase of over 2%, significantly outperforming the S&P 500's 0.3% rise, indicating strong market confidence in the company.
- Drug Development Potential: The analyst highlighted that Edgewise has several investigational programs that could position it favorably in the biotech sector, particularly the renewed interest in EDG-7500, a drug targeting hypertrophic cardiomyopathy, which may drive future growth.
- Impact of Clinical Data Release: Last week, Edgewise published long-term data on sevasemten for muscular dystrophy, showing that Becker muscular dystrophy patients stabilized function with treatment, contrasting sharply with expected functional decline, thereby laying a solid foundation for the company's future market performance.
- Multiple Drug Development Advantage: Edgewise is not only developing one high-potential drug but also two additional drugs in the high-demand cardiovascular segment, making its diversified development strategy a standout feature in the biotech industry and attracting investor interest.
See More
Analyst Raises Edgewise Price Target to $45
- Price Target Increase: Analyst Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, an increase of $11, reflecting confidence in the company's pipeline drug potential, which is expected to attract more investor interest.
- Positive Market Reaction: Following the price target increase, Edgewise's stock rose over 2% on Tuesday, significantly outperforming the S&P 500's 0.3% gain, indicating a bullish sentiment among investors towards the biotech firm.
- Pipeline Drug Potential: The analyst highlighted Edgewise's EDG-7500 drug targeting the high-demand market for hypertrophic cardiomyopathy (HCM), which could propel the company to a leading position in the biotech sector.
- Clinical Data Support: Recent long-term data from Edgewise's muscular dystrophy treatment sevasemten showed stabilization of function in Becker-type patients, contrasting sharply with expected declines from natural history data, further bolstering market confidence in its products.
See More
JPMorgan Chase's Stock Performance Disappoints
- Disappointing Revenue Growth: JPMorgan Chase's annualized revenue growth of 8.6% over the past five years is below the banking sector's standard, indicating a lack of competitive strength in revenue generation that may undermine investor confidence and limit future stock price appreciation.
- Weak Net Interest Margin: The bank's average net interest margin of 2.6% over the past two years reveals poor loan profitability, necessitating increased loan originations to compensate for lower earnings, which could elevate risk levels.
- Deteriorating Efficiency Ratio: Wall Street anticipates JPMorgan Chase's efficiency ratio will rise to 54% over the next 12 months, up from 51.7% last year, suggesting a decline in cost control capabilities that may further compress profit margins and impact overall financial health.
- Lack of Market Confidence: Despite the stock trading at $285.86 with a forward P/B ratio of 2.1, market sentiment remains skeptical about JPMorgan Chase's future performance, prompting analysts to recommend investors consider other stocks with greater potential, reflecting doubts about its long-term investment value.
See More
